The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Why was the FDA approval of esketamine so controversial among many ... withdrawal syndrome characterised by anxiety, dysphoria and depression, shaking, sweating and palpitations, and craving ...

Two cutting edge treatments for though-to-treat major depression are remarkably successful: TMS Therapy and Spravato (Esketamine) treatment. TMS is safe, medication free and covered by insurance.

It is now approved for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster ...